-
Rongchang's US$2.6 billion partnership ranks first, surpassing major pharmaceutical companies such as Roche and Daiichi Sankyo. Who will be among the top 10 ADC drugs in the world in 2021?
Time of Update: 2021-09-18
In 2019, Roche’s second ADC drug Polivy was approved for marketing by the FDA, combined with bendamustine and rituximab, for relapsed or refractory diffuse large B-cell lymphoma that had previously received at least 2 therapies (R/R DLBCL) patients .
-
Li Keqiang inspected and held a symposium with medical experts in Peking Union Medical College Hospital
Time of Update: 2021-09-18
Li Keqiang emphasized when inspecting and holding a symposium of medical experts in Peking Union Medical College HospitalLi Keqiang emphasized when inspecting and holding a symposium of medical exper
-
How can China's rare disease industry take the next step to crack the "sky-price drug" crisis?
Time of Update: 2021-09-18
Although with policy support, China has made great progress in the research and development of rare disease drugs in recent years, and more and more companies have entered this field, bringing new hope for the diagnosis and treatment of rare diseases .
-
Chia Tai Tianqing storms innovative drugs this year, 13 Class 1 new drugs approved for clinical trials
Time of Update: 2021-09-18
Source: CDE official website From September until now, CP Tianqing Pharmaceuticals has two Class 1 new drugs declared for clinical use, namely TQB2868 injection and TQB2916 injection.
-
The State Food and Drug Administration issued 63 medical device industry standards
Time of Update: 2021-09-18
On September 9, the State Food and Drug Administration website issued 63 medical device industry standards including YY 0671-2021 " Medical Devices Sleep Apnea Treatment Masks and Application Accessories" .
-
Technical guidelines for clinical trials of modified new drugs for ADHD drugs and children's chemicals released
Time of Update: 2021-09-18
On September 13, CDE issued the technical guidelines for clinical trials of attention deficit hyperactivity disorder drugs and the technical guidelines for clinical trials of improved new drugs for chemical drugs for children, which will be implemented from the date of issuance .
-
GlaxoSmithKline "Mepolizumab" is expected to be approved for listing in China in the near future
Time of Update: 2021-09-18
According to the announcement of the National Food and Drug Administration (NMPA) of China, the listing application status of the anti-IL-5 monoclonal antibody mepolizumab (mepolizumab) injection of GlaxoSmithKline (GSK) has been updated to "under approval".
-
Innovent and Bolt reached an agreement to jointly develop three anti-tumor drugs using antibody-immune stimulation coupling technology
Time of Update: 2021-09-13
(NASDAQ: BOLT) (hereinafter referred to as "Bolt"), a biotechnology company in the clinical stage, has created an effective binding antibody Targeting precision and new immunotherapies for the innate and adaptive immune systems have jointly announced today that the two parties have reached a new drug research and development agreement to jointly develop three antibody-immunostimulatory conjugate (ISAC) candidate drugs for the treatment of tumors .
-
Nuocheng Jianhua will bring its innovation pipeline to the 2021 Service Trade Fair to help healthy China
Time of Update: 2021-09-13
ST5011), With the theme of "science-driven innovation, patient needs-oriented" as the exhibition theme, Nuocheng Jianhua will exhibit the national "major new drug creation" special achievement -the new Bruton's tyrosine kinase (BTK) inhibitor abutinib, And other pipelines of innovative drugs under development .
-
Nature's in-depth review: Where will the new generation of mRNA therapy go?
Time of Update: 2021-09-13
A few days ago, a review published by Nature Reviews Materials made a detailed inventory of the development of LNP technology for mRNA delivery, and discussed the broad clinical application prospects and challenges that need to be solved for this technology in addition to infectious disease vaccines.
-
Six regulations for the renewal of National Procurement: the same common name can be selected by multiple candidates, and the rising cost allows the price to rise appropriately
Time of Update: 2021-09-13
In the last round of centralized procurement, the companies that participated in the bidding were 5 or less varieties selected by the difference, and the competition rules were determined on the basis of a comprehensive assessment of the changes in the market competition pattern and the price level .
-
Inventory of sales expenses of 15 multinational pharmaceutical companies in the first half of the year: the highest is more than 10 billion, and the proportion is declining year by year.
Time of Update: 2021-09-13
There is no doubt that although AstraZeneca’s overall sales expenditures accounted for the highest proportion of revenue among multinational pharmaceutical companies, data in recent years have clearly pointed out that its proportion has declined rapidly.
-
Columbotai: The third generation of Claudin 18.2 ADC reported to the clinic
Time of Update: 2021-09-13
(Source: CDE official website) SKB315 is a third-generation antibody conjugate drug (ADC) targeting Claudin 18.
It includes Sichuan Kelun Pharmaceutical Co.
, Sichuan Kelun Pharmaceutical Research Institute Co.
Sichuan Kelun Botai Bio-Pharmaceutical Co.
(Product pipeline source: Klus Pharma Inc.
-
Cinda is showing off!
Time of Update: 2021-09-13
In addition, the listing application of Sintilimab injection for second-line squamous non-small cell lung cancer is under review and is expected to be approved by the end of 2021 .
With the expansion of production capacity, the approval of new indications and the development of overseas markets, Sintilimab's sales are expected to increase .
-
Japan: Impurity particles in American Modena vaccine are visible to the naked eye. 1.63 million doses are suspended
Time of Update: 2021-09-13
A few days ago, the Shiji News Agency said that a total of about 570,000 doses of Modena vaccine were found to contain impurities.
-
Heavy varieties soared by 223.21%!
Time of Update: 2021-09-13
As an established pharmaceutical company, Fosun Pharma's generic drugs are also facing the impact of centralized procurement, and innovative products have become a strong "blood transfusion" support .
In the first half of the year, the sales revenue of Fosun Pharma's anti-tumor and immunomodulation core products increased by 256.
-
Another breakthrough after AlphaFold!
Time of Update: 2021-09-13
RoseTTAFold system on the cover of Science magazine In addition to AlphaFold, another system called RoseTTAFold developed by the research team at the University of Washington has also made important progress in predicting protein structure .
-
After the implementation of the new "Physician Law", what are the impacts of the primary medical and health field?
Time of Update: 2021-09-13
That is Article 11 of the "Physician Law": Those who have studied Chinese medicine in the form of a teacher for at least three years, or have proven expertise after years of practicing medical skills, are qualified and recommended by the professional organization of Chinese medicine or medical and health institutions commissioned by the health authorities of the people’s government at or above the county level, and can participate in the qualification examination of Chinese medicine doctors.
-
The market value has doubled: why the pioneering pharmaceutical industry is flying against the wind
Time of Update: 2021-09-13
Due to the discovery that a prostatic drug under research, Prokalamide, may have a potential effect on the treatment of new crowns, the share price of Chinese biotechnology company Kaiyuan Pharmaceutical in Hong Kong stocks has doubled several times, and its market value has soared from HK$6.
-
Multinational pharmaceutical companies are digging into the Chinese market and rely on new products to drive growth
Time of Update: 2021-09-13
Western drugmakers such as AstraZeneca, Bayer, Eli Lilly, Merck, Novartis, Novo Nordisk and Sanofi reported growth in drug sales in China in the first half of 2021 .
In the first half of this year, the company's sales in China increased by 11% at a constant exchange rate to US$3.
